New drug duo shows promise against tough uterine cancer
NCT ID NCT03835819
First seen Jun 11, 2026 · Last updated Jun 16, 2026 · Updated 2 times
Summary
This study tested a combination of two drugs, mirvetuximab soravtansine and pembrolizumab, in 18 people with a specific type of advanced or returning endometrial cancer that is microsatellite stable (MSS). The goal was to see if the combo could shrink tumors or stop them from growing for at least 6 months. The approach targets cancer cells while also helping the immune system fight the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Northwell Cancer Institute
Lake Success, New York, 11042, United States
-
University of Massachusetts
Worcester, Massachusetts, 01605, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.